ABOS Valuation

Acumen Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

1.605

+0.055(3.548%)1D

Overview
Forecast
Valuation
Earnings

ABOS Relative Valuation

ABOS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ABOS is overvalued; if below, it's undervalued.

Historical Valuation

Acumen Pharmaceuticals Inc (ABOS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -7.82. The fair price of Acumen Pharmaceuticals Inc (ABOS) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：1.60

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

0.58

P/B

Median3y

0.87

Median5y

0.88

-112.88

FCF Yield

Median3y

-39.53

Median5y

-31.08

Competitors Valuation Multiple

The average P/S ratio for ABOS's competitors is 1.05, providing a benchmark for relative valuation. Acumen Pharmaceuticals Inc Corp (ABOS) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ABOS.O

Acumen Pharmaceuticals Inc

Loss

Average P/S: 1.05

93.89M